Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Innovative Licensing and Access Pathway Designation from the UK Medicines and Healthcare Products Regulatory Agency
Wakefield, Mass., April 25th, 2023- Myrtelle Inc., (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
This article is featured on another website.
Now Available: Myrtelle ASGCT Symposium Presentation
Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.
Now Available: Myrtelle ASGCT Symposium Presentation
Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.
Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors
First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]
Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors
First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]